Causes for the development of lipodystrophy among HIV and AIDS patients

Abstract


Today, about 35 million people worldwide are infected with HIV. These patients often develop lipid metabolism disorder called lipodystrophy syndrome. Various clinical features of lipodystrophy are peripheral fat loss in the lower limbs, face and buttocks (lipoatrophy); central adiposity, i.e. excess fat accumulation in the abdomen, breasts or dorsocervical region (lipohypertrophy); lipoma development. These types of redistribution of the adipose tissue occur in isolation as well as combined. The article examines the following causes of the development of lipodystrophy: HIV-associated lipodystrophy, HAART-associated lipodystrophy and lipodystrophy caused by age-related changes. It is also pointed out that redistribution of the adipose tissue is more common among the HIV-patients who have had PI-based ART or nucleoside reverse transcriptase inhibitors-based ART (NRTIs).


About the authors

O V Azovtseva

Yaroslav-the-Wise Novgorod State University

Author for correspondence.
Email: olga-azovtseva@mail.ru

Ph.D. Associate Professor of the Department of Microbiology, Immunology and Infectious Diseases of Novgorod State University named after Yaroslav the Wise

M K Belous

Yaroslav-the-Wise Novgorod State University

Email: olga-azovtseva@mail.ru

References

  1. Pokrovsky VV, Ladnaya NN, Tushina OI, Buravtsova EV HIV Infection: Fact Sheet No. 40. M.: Federal Scientific and Methodological Center for AIDS Prevention and Control, 2015. 57 p.
  2. Melnikov VL, Aftaeva LN, Rybalkin SB, Mitrofanova NN Clinical and epidemiological features of HIV infection depending on the level of CD4 cells. Medical sciences. Hygiene and organization of public health. 2016. No. 3 (39). C. 113—118.
  3. Dvorak SI, Kryga LN, Vinogradova TN, Safonova PV, Zholobov VE, Plavinsky SL, Rassokhin VV Medico-social features of the “aging” of the HIV epidemic in St. Petersburg. HIV infection and immunosuppression. 2013. T. 5, No. 4. P. 82—89.
  4. Freitas P., Carvalho D. Lipodystrophy: beyond generalization? Panminerva Med. 2013; 55: 253—268.
  5. Carr A., Samaras K., Burton S., Law M., Freund J., Chisholm D.J. et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12; F5-8.
  6. Grinspoon S., Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. NEJM 2005; 352 (1): 48—62.
  7. Heath K.V., Hogg R.S., Chan K.J. et al. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS 2001; 15 (2): 231—9.
  8. Joly V., Flandre P., Meiffredy V. et al. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. Aids 2002; 16 (18): 2447—54.
  9. Sellmeyer D.E., Grunfeld C. Endocrine and metabolic disturbances in human immunodeficiency virus infection and the acquired immune deficiency syndrome. Endocr Rev. 1996; 17: 518—532.
  10. Hammond E., Nolan D., McKinnon E. et al. Assessing the contribution of ART, HIV and host factors to adipose tissue changes in HIV-infected individuals: risk profile for lipoatrophy. In: Program and Abstracts of the 7th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV; November 13—16, 2005; Dublin, Ireland. Supplement 3: L4, Abstract 2.
  11. Prosperi MC, Fabbiani M., Fanti I., Zaccarelli M., Colafigli M., Mondi A., D'Avino A., Borghetti A., Cauda R., Di Giambenedetto S. Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study. BMC Infect Dis. 2012; 12: 296.
  12. Baker J., Ayenew W., Quick H., Hullsiek K.H., Tracy R., Henry K., Duprez D., Neaton J.D. High-density lipoprotein particles and markers of inflammation and thrombotic activity in patients with untreated HIV infection. J Infect Dis. 2010; 201: 285—292.
  13. Vaidya SA, Korner C., Sirignano MN, Amero M., Bazner S., Rychert J., Allen TM, Rosenberg ES, Bosch RJ, Altfeld M. Tumor necrosis factor α is associated with viral control and early disease progression in patients with HIV. J Infect Dis. 2014; 210: 1042—1046.
  14. Simha V., Garg A. Lipodystrophy: lessons in lipid and energy metabolism. Current Opinion in Lipidology 2006; 17 (2): 162—169.
  15. Van Wijk J.P., Castro Cabezas M., de Koning E.J.P., Rabelink T.J., van der Geest R., Hoepelman I.M. In vivo evidence of impaired peripheral fatty acid trapping in patients with human immunodeficiency virus-associated lipodystrophy. J. Clin. Endocrinol. Metab. 2006; 90 (6): 3575—3582.
  16. Cohen MS, Chen YQ, McCauley M., Gamble T., Hosseinipour MC, Kumarasamy N., Hakim J., Kumwenda J., Grinsztejn B., Pilotto JH, Godbole SV, Mehendale S., Chariyalertsak S., Santos BR, Mayer KH, Hoffman IF, Eshleman SH, Piwowar-Manning E., Wang L., Makhema J. Prevention of HIV-1 infection with early antiretroviral therapy. New England Journal of Medicine. 2011. No. 365. P. 493—505.
  17. Steven AS, Ellen SH, Laura S. Quality of Life Among Individuals with HIV Starting Antiretroviral Therapy in Diverse Resource-Limited Areas of the World. AIDS and Behavior. 2012. No. 16 (2). P. 266—277.
  18. The strategic use of antiretrovirals to help end the HIV epidemic / WHO. URL: http://apps.who.int/iris/bitstream/ 10665/75184/1/9789241503921_eng.pdf? Ua = 1 (circulation date 14.10.2014).
  19. Pokrovsky V.V. Tuberculosis and HIV infection — the threat of a double epidemic: speech at the All-Russian conference “Tuberculosis and HIV infection — the threat of a double epidemic. Actual issues of prevention, diagnosis and treatment”/ FNMTS on prevention and fight against AIDS. URL: http://itar-tass.com/obschestvo/ 1481670 (circulation date 02.10.2014).
  20. Fisher S.D., Miller T.L., Lipshultz S.E. Impact of HIV and highly active antiretroviral therapy on leukocyte adhesion molecules, arterial inflammation, dyslipidemia, and atherosclerosis. Atherosclerosis. 2006; 185: 1—11.
  21. Bernasconi E., Boubaker K., Junghans C. et al. Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: The Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 2002; 31 (1): 50—5.
  22. Penzak S.R., Chuck S.K. Hyperlipidemia associated with HIV protease inhibitor use: pathophysiology, prevalence, risk factors and treatment. Scand. J. Infect. Dis. 2000: 32: 111—123.
  23. Khasanov GR Syndrome of lipodystrophy in people with HIV infection. Epidemiology and infectious diseases. Topical issues. 2014. No. 3. C. 63—69.

Statistics

Views

Abstract - 277

PDF (Russian) - 240

Cited-By


PlumX

Dimensions


Copyright (c) 2018 Azovtseva O.V., Belous M.K.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies